Anna Maria Borruto

Dr. Anna Maria Borruto

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Pain
Verified
Journal Article
Open access
XWXuhong Wei
Xuhong Wei
MCMaria Virginia Centeno
Maria Virginia Centeno
WRWenjie Ren
Wenjie Ren
ABAnna Maria Borruto
Anna Maria Borruto
Daniele ProcissiDaniele Procissi
Daniele Procissi
AAApkar Vania Apkarian
Apkar Vania Apkarian
Accumulating evidence suggests hippocampal impairment under the chronic pain phenotype. However, it is unknown whether neuropathic behaviors are related to dysfunction of the hippocampal circuitry. Here, we enhanced hippocampal activity by pharmacological, optogenetic, and chemogenetic techniques to determine hippocampal influence on neuropathic pain behaviors. We found that excitation of the dorsal (DH), but not the ventral (VH) hippocampus induces analgesia in 2 rodent models of neuropathic pain (SNI and SNL) and in rats and mice. Optogenetic and pharmacological manipulations of DH neurons demonstrated that DH-induced analgesia was mediated by N-Methyl-D-aspartate and μ-opioid receptors. In addition to analgesia, optogenetic stimulation of the DH in SNI mice also resulted in enhanced real-time conditioned place preference for the chamber where the DH was activated, a finding consistent with pain relief. Similar manipulations in the VH were ineffective. Using chemo-functional magnetic resonance imaging (fMRI), where awake resting-state fMRI was combined with viral vector-mediated chemogenetic activation (PSAM/PSEM89s) of DH neurons, we demonstrated changes of functional connectivity between the DH and thalamus and somatosensory regions that tracked the extent of relief from tactile allodynia. Moreover, we examined hippocampal functional connectivity in humans and observe differential reorganization of its anterior and posterior subdivisions between subacute and chronic back pain. Altogether, these results imply that downregulation of the DH circuitry during chronic neuropathic pain aggravates pain-related behaviors. Conversely, activation of the DH reverses pain-related behaviors through local excitatory and opioidergic mechanisms affecting DH functional connectivity. Thus, this study exhibits a novel causal role for the DH but not the VH in controlling neuropathic pain–related behaviors.

Verified
Journal Article
Open access
PDF file
MUMassimo Ubaldi
Massimo Ubaldi
NCNazzareno Cannella
Nazzareno Cannella
ABAnna Maria Borruto
Anna Maria Borruto
MPMichele Petrella
Michele Petrella
Maria Vittoria Micioni Di BonaventuraMaria Vittoria Micioni Di Bonaventura
Maria Vittoria Micioni Di Bonaventura
RCRoberto Ciccocioppo
Roberto Ciccocioppo
Nociceptin/orphanin FQ (N/OFQ) is a 17-residue neuropeptide that binds the nociceptin opioid-like receptor (NOP). N/OFQ exhibits nucleotidic and aminoacidics sequence homology with the precursors of other opioid neuropeptides but it does not activate either MOP, KOP or DOP receptors. Furthermore, opioid neuropeptides do not activate the NOP receptor. Generally, activation of N/OFQ system exerts anti-opioids effects, for instance toward opioid-induced reward and analgesia. The NOP receptor is widely expressed throughout the brain, whereas N/OFQ localization is confined to brain nuclei that are involved in stress response such as amygdala, BNST and hypothalamus. Decades of studies have delineated the biological role of this system demonstrating its involvement in significant physiological processes such as pain, learning and memory, anxiety, depression, feeding, drug and alcohol dependence. This review discusses the role of this peptidergic system in the modulation of stress and stress-associated psychiatric disorders in particular drug addiction, mood, anxiety and food-related associated-disorders. Emerging preclinical evidence suggests that both NOP agonists and antagonists may represent a effective therapeutic approaches for substances use disorder. Moreover, the current literature suggests that NOP antagonists can be useful to treat depression and feeding-related diseases, such as obesity and binge eating behavior, whereas the activation of NOP receptor by agonists could be a promising tool for anxiety.

6 September 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
MFMarion Friske
Marion Friske
ETEva C. Torrico
Eva C. Torrico
MHMaximilian J. W. Haas
Maximilian J. W. Haas
ABAnna Maria Borruto
Anna Maria Borruto
FGFrancesco Giannone
Francesco Giannone
Rainer SpanagelRainer Spanagel
Rainer Spanagel
Currently available clinical treatments on alcohol use disorder (AUD) exhibit limited efficacy and new druggable targets are required. One promising approach to discover new molecular treatment targets involves the transcriptomic profiling of brain regions within the addiction neurocircuitry, utilizing animal models and postmortem brain tissue from deceased patients with AUD. Unfortunately, such studies suffer from large heterogeneity and small sample sizes. To address these limitations, we conducted a cross-species meta-analysis on transcriptome-wide data obtained from brain tissue of patients with AUD and animal models. We integrated 36 cross-species transcriptome-wide RNA-expression datasets with an alcohol-dependent phenotype vs. controls, following the PRISMA guidelines. In total, we meta-analyzed 964 samples – 502 samples from the prefrontal cortex (PFC), 282 nucleus accumbens (NAc) samples, and 180 from amygdala (AMY). The PFC had the highest number of differentially expressed genes (DEGs) across rodents, monkeys, and humans. Commonly dysregulated DEGs suggest conserved cross-species mechanisms for chronic alcohol consumption/AUD comprising MAPKs as well as STAT, IRF7, and TNF. Furthermore, we identified numerous unique gene sets that might contribute individually to these conserved mechanisms and also suggest novel molecular aspects of AUD. Validation of the transcriptomic alterations on the protein level revealed interesting targets for further investigation. Finally, we identified a combination of DEGs that are commonly regulated across different brain tissues as potential biomarkers for AUD. In summary, we provide a compendium of genes that are assessable via a shiny app, and describe signaling pathways, and physiological and cellular processes that are altered in AUD that require future studies for functional validation.

12 November 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
ABAnna Maria Borruto
Anna Maria Borruto
YFYannick Fotio
Yannick Fotio
SSSerena Stopponi
Serena Stopponi
GBGloria Brunori
Gloria Brunori
MPMichele Petrella
Michele Petrella
RCRoberto Ciccocioppo
Roberto Ciccocioppo
Background and Purpose: Nociceptin/orphanin FQ (N/OFQ) peptide and its cognate receptor (NOP) are widely expressed in mesolimbic brain regions where they play an important role in modulating reward and motivation. Early evidence suggested that NOP receptor activation attenuates the rewarding effects of drugs of abuse, including alcohol. However, emerging data indicate that NOP receptor blockade also effectively attenuates alcohol drinking and relapse. To advance our understanding of the role of the N/OFQ‐NOP receptor system in alcohol abuse, we examined the effect of NOP receptor blockade on voluntary alcohol drinking at the neurocircuitry level.Experimental Approach: Using male and female genetically selected alcohol‐preferring Marchigian Sardinian (msP) rats, we initially evaluated the effects of the selective NOP receptor antagonist LY2817412 (3, 10, and 30 mg·kg−1, p.o.) on alcohol consumption in a two‐bottle free‐choice paradigm. We then microinjected LY2817412 (3 and 6 μg·μl−1 per rat) in the central nucleus of the amygdala (CeA), ventral tegmental area (VTA), and nucleus accumbens (NAc).Key Results: Peripheral LY2817412 administration dose‐dependently and selectively reduced voluntary alcohol intake in male and female msP rats. Central injections of LY2817412 markedly attenuated voluntary alcohol intake in both sexes following administration in the CeA and VTA but not in the NAc.Conclusion and Implications: The present results revealed that the CeA and VTA are neuroanatomical substrates that mediate the effects of NOP receptor antagonism on alcohol consumption. Overall, our findings support the potential of NOP receptor antagonism as a treatment strategy to attenuate alcohol use and addiction.

20 July 2021 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
ABAnna Maria Borruto
Anna Maria Borruto
YFYannick Fotio
Yannick Fotio
SSSerena Stopponi
Serena Stopponi
MPMichele Petrella
Michele Petrella
SCSara De Carlo
Sara De Carlo
RCRoberto Ciccocioppo
Roberto Ciccocioppo

1 July 2020 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
YFYannick Fotio
Yannick Fotio
ABAnna Maria Borruto
Anna Maria Borruto
FBFederica Benvenuti
Federica Benvenuti
GDGregory Demopulos
Gregory Demopulos
GGGeorge Gaitanaris
George Gaitanaris
RCRoberto Ciccocioppo
Roberto Ciccocioppo